pocketful logo
Godavari Drugs Ltd logo

Godavari Drugs Ltd

NSE: BSE: 530317

81.77

(-1.35%)

Wed, 18 Mar 2026, 01:57 pm

Godavari Drugs Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    61.93

  • Net Profit

    4.38

  • P/B

    1.52

  • Sector P/E

    39.71

  • P/E

    15.03

  • EV/EBITDA

    9.98

  • Debt/Equity (Industry)

    0.16

  • Interest Cover (Industry)

    20.07

  • ROCE (Industry)

    20.49

  • RONW (Industry)

    17.59

  • ROE

    10.64

  • ROCE

    10.06

  • Debt/Equity

    1.48

  • EPS (TTM)

    5.78

  • Dividend Yield

    0

  • Book Value

    57.56

  • Interest Cover

    2.19

Analysis

all

thumbs up icon

Pros

  • Godavari Drugs is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Godavari Drugs is profitable, therefore cash runway is not a concern.
  • Godavari Drugs is profitable, therefore cash runway is not a concern.
  • Debt is covered by short term assets, assets are 2.3x debt.
  • Godavari Drugs's cash and other short term assets cover its long term commitments.
thumbs up icon

Cons

  • Unable to evaluate Godavari Drugs's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Godavari Drugs's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Debt is not well covered by operating cash flow (15.1%, less than 20% of total debt).
  • The level of debt compared to net worth has increased over the past 5 years (31.5% vs 129.5% today).
  • Interest payments on debt are not well covered by earnings (EBIT is 2x annual interest expense, ideally 3x coverage).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters52.6152.6152.6352.6352.63
FII00000
DII0.500.500.500.500.50
Public46.8946.8946.8746.8746.87
Government00000

Read More

Technical Analysis

RSI

56.74

MACD

-0.54

50 DMA

86.52

200 DMA

85.03

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic123.81103.8590.7883.8970.8263.9343.97
Fibonacci103.8596.2391.5183.8976.2771.5563.93
Camarilla83.2081.3779.5483.8975.8874.0572.22

Pivots Level: Classic

R3

+39.92

123.81

R2

+19.96

103.85

R1

+6.89

90.78

83.89
83.89
Pivot Point
LTP: 86.67

S1

-13.07

70.82

S2

-19.96

63.93

S3

-39.92

43.97

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    82.66

  • 20-EMA

    82.74

  • 30-EMA

    83.26

  • 50-EMA

    83.66

  • 100-EMA

    83.97

  • 200-EMA

    86.44

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
21 Jan 2026egm
14 Nov 2025board-meetingsQuarterly Results
04 Aug 2025agm
30 May 2024agm
21 Jul 2023agm
25 Apr 2022agm
23 Jul 2021agm

Read More

Peer Comparison

Godavari Drugs Ltd logo

Godavari Drugs Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Lupin Ltd logo

Lupin Ltd

Read More

Godavari Drugs Ltd About

Godavari Drugs engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and its intermediates through its manufacturing facility at Nanded, Maharashtra, India.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1987

Headquarters

CEO

Ghanshyam Jaju

Employees

Contact

Website icon

Website

http://www.godavaridrugs.com

Email icon

Email

info@godavaridrugs.com

Phone icon

Phone

91-40-27849700/27844557

Location icon

Location

Mayfair 1-8-303-34, Sardar Patel Road, Secunderabad, Andhra Pradesh, 500003

Read More

Godavari Drugs Ltd Company History

YearHistory
1987
  • GODAVARI DRUGS LIMITED was incorporated as a private limited company on December 2.
1988
  • The company set up a project to manufacture 180 TPA of SULPHAMETHOXAZOLE.
1989
  • The project to manufacture SULPHAMETHOXAZOLE was fully commissioned on July 3.
1992
  • The company was converted into a public limited company on September 25.
2012
  • The Board appointed Mr. Mohit Jaju as an Additional Director effective from May 10.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
TRADELINK EXIM INDIA PVT LTDBuy3921798.8816 Jan 2026
MADHUSUDHAN GUNDABuy40000106.226 Aug 2024
MADHUSUDHAN GUNDASell3389211226 Aug 2024
PRASHANT SHRIMALSell4183393.5215 Jun 2023
MOHIT JAJUBuy7000087.9906 Jun 2023
PRASHANT SHRIMALSell1551678806 Jun 2023
SUSHMA KAKANIBuy700008806 Jun 2023
YUGA STOCKS AND COMMODITIES PRIVATE LIMITED .Buy4500075.7819 Dec 2022
ARHAM SHARE PRIVATE LIMITEDBuy4056475.819 Dec 2022
ARHAM SHARE PRIVATE LIMITEDSell4056474.9319 Dec 2022

Read More

Godavari Drugs Ltd News

Godavari Drugs EGM Approves Equity Share & Warrant Issue

Godavari Drugs Limited successfully concluded its 1st EGM for FY 2025-26 on February 12, 2026, with shareholders approving two special resolutions for preferential equity shares and convertible warrants issuance.

12 Feb 2026

co actions results

Godavari Drugs Q3FY26 Results & Loan Approval

Godavari Drugs reported Q3FY26 net profit of ₹75.76 lakhs with revenue of ₹2218.43 lakhs. Board approved ₹5.50 crore working capital loan from ICICI Bank for new order execution.

11 Feb 2026

co actions results

Godavari Drugs Board Approves Preferential Issue

Godavari Drugs Limited board approves preferential issue of 23.60 lakh convertible warrants and 25.97 lakh equity shares at ₹89 each to promoters and non-promoters, subject to shareholder approval in EGM scheduled for February 12, 2026.

15 Jan 2026

co actions results

Godavari Drugs clarifies share price movement

Godavari Drugs Limited responds to BSE inquiry on share price volatility, stating no unpublished price sensitive information exists and attributing movement to market-driven demand-supply factors.

08 Jan 2026

stocks

Godavari Drugs Reports Mixed Q2 Performance with Revenue Growth but Margin Pressure

Godavari Drugs Limited reported revenue from operations of Rs 2,664.04 lakhs for the quarter ended September 30, 2025, up from Rs 2,608.79 lakhs in the same quarter last year, with net profit rising to Rs 100.07 lakhs from Rs 108.86 lakhs. The company's half-year revenue reached Rs 5,046.07 lakhs compared to Rs 5,829.54 lakhs in the previous year, while net profit for the six-month period stood at Rs 204.13 lakhs versus Rs 271.94 lakhs last year.

14 Nov 2025

earnings

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800